본문 바로가기
KERD
논문KCI 등재

Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

주제분류병리학

초록

Background: Non-invasive clinical algorithms for the detection of liver fibrosis (LF) can reduce the need for liver biopsy (LB). We explored the implementation of two serum biomarkers, enhanced liver fibrosis (ELF) and Mac-2 binding protein glycosylation isomer (M2BPGi), in clinical algorithms for LF in chronic hepatitis B (CHB) patients. Methods: Two clinical algorithms were applied to 152 CHB patients: (1) transient elastography (TE) followed by biomarkers (TE/ELF and TE/M2GPGi); (2) biomarker test followed by TE (ELF/TE and M2BPGi/TE). Using the cut-off value or index for the detection of advanced LF (TE≥F3; 9.8 in ELF and 3.0 in M2BPGi), LB was expected to be performed in cases with discordant TE and biomarker results. Results: In both algorithms, the expected number of LBs was lower when using M2BPGi than when using ELF (TE/ELF or ELF/TE, 13.2% [N=20]; TE/M2BPGi or M2BPGi/TE, 9.9% [N=15]), although there was no statistical difference (P=0.398). In the TE low-risk group (TE≤F2), the discordance rate was significantly lower in the TE/M2BPGi approach than in the TE/ELF approach (1.5% [2/136] vs. 11.0% [15/136], P=0.002). In the biomarker low-risk group, there was no significant difference between the ELF/TE and M2BPGi/TE approaches (3.9% [5/126] vs. 8.8% [13/147], P=0.118). Conclusions: Both ELF and M2BPGi can be implemented in non-invasive clinical algorithms for assessing LF in CHB patients. Given the lowest possibility of losing advanced LF cases in the low-risk group when using the TE/M2BPGi approach, this combination seems useful in clinical practice.

Abstract

Background: Non-invasive clinical algorithms for the detection of liver fibrosis (LF) can reduce the need for liver biopsy (LB). We explored the implementation of two serum biomarkers, enhanced liver fibrosis (ELF) and Mac-2 binding protein glycosylation isomer (M2BPGi), in clinical algorithms for LF in chronic hepatitis B (CHB) patients. Methods: Two clinical algorithms were applied to 152 CHB patients: (1) transient elastography (TE) followed by biomarkers (TE/ELF and TE/M2GPGi); (2) biomarker test followed by TE (ELF/TE and M2BPGi/TE). Using the cut-off value or index for the detection of advanced LF (TE≥F3; 9.8 in ELF and 3.0 in M2BPGi), LB was expected to be performed in cases with discordant TE and biomarker results. Results: In both algorithms, the expected number of LBs was lower when using M2BPGi than when using ELF (TE/ELF or ELF/TE, 13.2% [N=20]; TE/M2BPGi or M2BPGi/TE, 9.9% [N=15]), although there was no statistical difference (P=0.398). In the TE low-risk group (TE≤F2), the discordance rate was significantly lower in the TE/M2BPGi approach than in the TE/ELF approach (1.5% [2/136] vs. 11.0% [15/136], P=0.002). In the biomarker low-risk group, there was no significant difference between the ELF/TE and M2BPGi/TE approaches (3.9% [5/126] vs. 8.8% [13/147], P=0.118). Conclusions: Both ELF and M2BPGi can be implemented in non-invasive clinical algorithms for assessing LF in CHB patients. Given the lowest possibility of losing advanced LF cases in the low-risk group when using the TE/M2BPGi approach, this combination seems useful in clinical practice.

참고문헌 (36)

  1. Rockey DC, "Fibrosis—a common pathway to organ injury and failure", N Engl J Med, 372, pp.1138~1149 (2015)
  2. "At last a global response to viral hepatitis" (2020)[URL]
  3. Pellicoro A, "Liver fibrosis and repair : immune regulation of wound healing in a solid organ", Nat Rev Immunol, 14, pp.181~194 (2014)
  4. Soresi M, "Non invasive tools for the diagnosis of liver cirrhosis", World J Gastroenterol, 20, pp.18131~18150 (2014)
  5. Bravo AA, "Liver biopsy", N Engl J Med, 344, pp.495~500 (2001)
  6. Rousselet MC, "Sources of variability in histological scoring of chronic viral hepatitis", Hepatology, 41, pp.257~264 (2005)
  7. Liu T, "Molecular serum markers of liver fibrosis", Biomark Insights, 7, pp.105~117 (2012)
  8. Kim SU, "Clinical application of liver stiffness measurement using transient elastography : a surgical perspective", Digestion, 88, pp.258~265 (2013)
  9. Tsochatzis EA, "Elastography for the diagnosis of severity of fibrosis in chronic liver disease : a meta-analysis of diagnostic accuracy", J Hepatol, 54, pp.650~659 (2011)
  10. Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)
  11. Friedrich-Rust M, "Critical comparison of elastography methods to assess chronic liver disease", Nat Rev Gastroenterol Hepatol, 13, pp.402~411 (2016)
  12. Lichtinghagen R, "influence factors and proposed cut-offvalues", J Hepatol, 59, pp.236~242 (2013)
  13. Narimatsu H, "Development of M2BPGi : a novel fibrosis serum glyco-biomarker for chronic hepatitis", cirrhosis diagnostics, 2015, pp.12, 683~693
  14. Shirabe K, "Mac-2 binding protein glycan isomer(M2BPGi)is a new serum biomarker for assessing liver fibrosis : more than a biomarker of liver fibrosis", J Gastroenterol, 53, pp.819~826 (2018)
  15. 조선영, "Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis", Annals of Laboratory Medicine, 38(4), pp.289~290 (2018), 대한진단검사의학회
  16. Tamaki Nobuharu, "Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases", Annals of Laboratory Medicine, 41(1), pp.16~24 (2021), 대한진단검사의학회[DOI]
  17. Jang Se Young, "Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases", Annals of Laboratory Medicine, 41(3), pp.302~309 (2021), 대한진단검사의학회[DOI]
  18. 문희원, "Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases", Annals of Laboratory Medicine, 38(4), pp.331~337 (2018), 대한진단검사의학회
  19. Dong Wook Jekarl, "Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFAM2BP) Among Chronic Hepatitis B Patients", Annals of Laboratory Medicine, 38(4), pp.348~354 (2018), 대한진단검사의학회
  20. Castéra L, "Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C", J Hepatol, 52, pp.191~198 (2010)
  21. Wong GL, "Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B", Aliment Pharmacol Ther, 39, pp.197~208 (2014)
  22. Petta S, "The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease", Liver Int, 35, pp.1566~1573 (2015)
  23. Calès P, "Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C : agreement or combination?", Aliment Pharmacol Ther, 45, pp.991~1003 (2017)
  24. European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
  25. Tapper EB, "Use of liver imaging and biopsy in clinical practice", N Engl J Med, 377, pp.2296~2297 (2017)
  26. Yoneda M, "Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods", J Gastroenterol, 53, pp.181~196 (2018)
  27. "Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines 2021" (2021)[URL]
  28. Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
  29. Kuno A, "A serum"sweet-doughnut"protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis", Sci Rep, 3, pp.1065~ (2013)
  30. Sim J, "The kappa statistic in reliability studies: use, interpretation, and sample size requirements", Phys Ther, 85, pp.257~268 (2005)
  31. Inadomi C, "Accuracy of the enhanced liver fibrosis test, and combination of the enhanced liver fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease", Hepatol Res, 50, pp.682~692 (2020)
  32. Boursier J, "A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis", J Hepatol, 66, pp.1158~1165 (2017)
  33. Ellis EL, "Clinical evidence for the regression of liver fibrosis", J Hepatol, 56, pp.1171~1180 (2012)
  34. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5 year open-label follow up study", Lancet, 381, pp.468~475 (2013)
  35. Faul F, "G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences", Behav Res Methods, 39, pp.175~191 (2007)
  36. 김혜영, "Statistical notes for clinical researchers: Sample size calculation 2. Comparison of two independent proportions", Restorative Dentistry and Endodontics, 41(2), pp.154~156 (2016), 대한치과보존학회

관련 논문AI추천

Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B김도영, 김범경, 김승업, 박준용, 안상훈, 한광협, Hyon-Suk Kim, Ja Yoon Heo, Kijun Song, Young Nyun Park거트앤리버 소화기연관학회협의회 · Gut and Liver2018 · 제12권 제2호Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFAM2BP) Among Chronic Hepatitis B Patients권정현, 김명신, 김용구, 성필수, 유혜인, 윤승규, 이성원, 이승옥, 최현주, Dong Wook Jekarl대한진단검사의학회 · Annals of Laboratory Medicine2018 · 제38권 제4호Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases김한아, 문희원, 박미경, 윤여민, 최원혁, 허미나대한진단검사의학회 · Annals of Laboratory Medicine2018 · 제38권 제4호Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver DiseasesIzumi Namiki, Kurosaki Masayuki, Loomba Rohit, Tamaki Nobuharu대한진단검사의학회 · Annals of Laboratory Medicine2021 · 제41권 제1호Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease윤기태, 조애정, 조영윤, Baek Yang Hyun, Jang Se Young, Jo Hoon Gil, Jun Dae Won, Moon Sang Yi거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제2호Serial Liver Stiffness Measurement and Serum Biomarkers Are Not Strong Predictors of the Regression of Fibrosis among Chronic Hepatitis B Patients Receiving Antiviral Therapy Based on Triple Liver BiopsiesChen Shuyan, Kong Yuanyuan, Ou Xiaojuan, Sun Yameng, Wang Bingqiong, Wu Xiaoning, Xu Xiaoqian, You Hong, Zhang Jiayi, Zhao Xinyu, Zhou Jialing거트앤리버 소화기연관학회협의회 · Gut and Liver2025 · 제19권 제6호

이 간행물의 다른 논문 (20건)